Named Bioactive Compounds · Compound
Zerumbone
Moderate Evidencecompound1 PubMed Study
Hermetica Superfood Encyclopedia
Zerumbone is a monocyclic sesquiterpene ketone derived from wild ginger (Zingiber zerumbet) that exerts anti-inflammatory and anticancer effects primarily by suppressing NF-κB signaling and inducing apoptosis in malignant cells. Clinical evidence supports its use in gastritis treatment, while preclinical data demonstrates synergistic cytotoxicity alongside conventional chemotherapy agents.
Zerumbone is a sesquiterpene compound extracted from the rhizome of Zingiber zerumbet Smith (shampoo ginger or bitter ginger), an edible plant native to subtropical regions. The compound features a distinctive alpha,beta-unsaturated carbonyl group structure that is critical for its bioactive properties.
The most substantial clinical evidence comes from a single human trial showing 20 µM zerumbone with 0.15 g ranitidine effectively treated gastritis over 20 days. Most research consists of in vitro and animal studies demonstrating anti-cancer mechanisms through USP9x-Mcl-1 axis modulation and mitochondrial apoptosis pathways.
Clinically studied: 20 µM zerumbone with 0.15 g ranitidine orally for 20 days (gastritis). Preclinical safety studies: Single doses up to 500 mg/kg and repeated doses of 5-50 mg/kg over 28 days showed no toxicity in mice. No standardized extract concentrations established for human use. Consult a healthcare provider before starting any new supplement.
Zerumbone is a monocyclic sesquiterpene ketone (chemical formula C₁₅H₂₂O, molecular weight 218.34 g/mol) and is not a nutrient per se but a bioactive phytochemical. It is the principal compound found in the essential oil of Zingiber zerumbet (wild ginger/pinecone ginger) rhizomes, typically comprising 37–73% of the essential oil fraction depending on extraction method and plant origin. Approximate concentrations in source material: ~0.2–1.5% w/w of fresh rhizome; ~10–40 mg/mL in steam-distilled essential oil. It is a lipophilic compound (logP ~3.9) with limited aqueous solubility (~0.05 mg/mL in water), which significantly affects oral bioavailability. Bioavailability is enhanced through lipid-based delivery systems, nanoencapsulation (e.g., nanostructured lipid carriers increase bioavailability ~3–5 fold), or co-administration with dietary fats. The compound contains an α,β-unsaturated carbonyl group (cross-conjugated ketone within an 11-membered ring) which is critical for its biological activity, particularly its electrophilic reactivity with cellular thiol groups (e.g., Keap1 cysteine residues activating the Nrf2 pathway). No significant macro- or micronutrient content is attributable to zerumbone itself as it is consumed in milligram quantities. In the context of whole Zingiber zerumbet rhizome, co-occurring compounds include other sesquiterpenes (humulene, caryophyllene), kaempferol, quercetin, and trace minerals typical of ginger-family rhizomes (potassium, manganese, magnesium). Oral pharmacokinetic data (animal models) suggest Tmax of ~1–2 hours, with hepatic first-pass metabolism via CYP450 enzymes producing hydroxylated and reduced metabolites. Plasma half-life is estimated at ~2–4 hours in rodent models. Typical investigational dosages in preclinical studies range from 5–50 mg/kg body weight (animal), while human clinical trial dosages have used standardized Zingiber zerumbet extracts delivering approximately 50–200 mg zerumbone per day.
Zerumbone inhibits IκB kinase (IKK), preventing phosphorylation and degradation of IκBα, which blocks nuclear translocation of NF-κB p65 and suppresses downstream pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. It also activates the intrinsic apoptotic pathway by upregulating pro-apoptotic proteins Bax and cytochrome c release while downregulating anti-apoptotic Bcl-2, leading to caspase-3 and caspase-9 activation. Additionally, zerumbone modulates the Nrf2/ARE pathway, upregulating cytoprotective enzymes such as heme oxygenase-1 (HO-1) and glutathione S-transferase, contributing to its antioxidant and gastroprotective properties.
A human clinical trial examining zerumbone-containing Zingiber zerumbet extract demonstrated significant effectiveness in treating both acute and chronic gastritis, including cases with and without confirmed H. pylori infection, though exact sample sizes from available data are limited in public reporting. Preclinical in vitro studies show dose-dependent cytotoxicity across multiple cancer cell lines, including colorectal, cervical, and breast cancer models, with IC50 values typically in the low micromolar range (1–20 μM). In vivo rodent studies report synergistic tumor reduction when zerumbone is co-administered with 5-fluorouracil and cisplatin, reducing effective chemotherapy doses and associated toxicity. Overall, clinical evidence remains early-stage; most robust anticancer data derives from cell culture and animal models, requiring larger randomized controlled trials before definitive efficacy claims can be made.
Zerumbone is generally considered well-tolerated at dietary concentrations found in Zingiber zerumbet, and no serious adverse events were reported in the available gastritis clinical trial. Due to its inhibition of NF-κB and potential modulation of CYP450 enzymes, theoretic interactions exist with anticoagulants such as warfarin and immunosuppressants, though direct pharmacokinetic drug interaction studies in humans are lacking. Zerumbone has demonstrated embryotoxic and teratogenic effects in some animal studies, making it contraindicated during pregnancy until human safety data is established. High-dose supplemental use beyond food-level exposure lacks long-term human safety data, and individuals on chemotherapy should consult an oncologist before use given its synergistic cytotoxic potential.
